Cerluten vs Vladonix

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Standard Khavinson-class dosing protocols use oral capsule formulations in 10–20 day cycles at 5–10mg per cycle (divided doses), followed by rest intervals — consistent with the gene-regulatory rather than continuous-receptor-occupancy mechanism proposed for this peptide class. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.

Short peptide complex penetrates cell nuclei and modulates gene expression in thymic and T-lymphocyte cells. Promotes T-cell maturation, normalizes CD4/CD8 ratios, and supports cytokine balance.

Vladonix is a Khavinson-class peptide bioregulator derived from thymus tissue, developed as part of Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore immune function in aging subjects by modulating gene expression in thymic epithelial cells and thymus-dependent lymphocyte populations. As a thymic tissue-derived bioregulator, Vladonix shares its mechanistic framework with thymalin, the better-characterized Khavinson thymus compound; both are proposed to interact with chromatin regulatory elements in thymic cells to reactivate gene expression programs that decline with immunosenescence, potentially restoring T-cell maturation and peripheral immune competence. Published research from the Khavinson group on thymus-derived short peptides, including thymalin, has demonstrated human hematopoietic stem cell differentiation activity, immune modulation in aged subjects, and class-level evidence for thymic peptide bioregulation, providing biological plausibility for this compound class. Vladonix has no FDA approval and no approved indication in any Western jurisdiction; it is the commercial thymic bioregulator product distinct from thymalin but sharing the same class evidence framework, with no independent published clinical trials specific to this formulation, and its use is confined to the Russian integrative and anti-aging medicine context.